biote Corp.

NASDAQ:BTMD

Medical - Care Facilities

Healthcare
$1.23 +0.22%

+$0.01 today

Market cap
$54.25M
Beta
1.66
P/E (TTM)
4.5
EPS (TTM)
$0.51
52W Low $1.27High $4.75

Volume 0.11M

Average 0.25M

BTMD Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

biote Corp.NASDAQ: BTMD

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $21.54M (cash outflow) rose 854.3% year over year, ahead of the -13.8% change in trailing-twelve-month financing cash flow. Sequentially, it rose 135.9% from the prior quarter.

Context

  • Financing cash flow amounted to 22.7% of revenue in FY2025, down 15.9 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +854.3% holds above the trailing-twelve-month pace of -13.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$21.54M+135.9% QoQ
Last fiscal yearDec 2025
-$43.56M-42.8% YoY
LTMMar 2026
-$62.84M-13.8% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+854.3%——
1 year-42.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(43.56M) USD
Year-over-year change
+42.8%

Financing Cash Flow vs competitors

How BTMD compares with its peers on the latest reported figures

  • BTMD's LTM Mar 2026 financing cash flow of $62.84M is the 2nd largest of the 11 companies compared; the peer median is $18.59M.
  • Its year-over-year change of -13.8% is the 8th highest of 10, against a peer median of +8.7%.
  • Financing cash flow amounts to 33.4% of revenue for BTMD, versus a peer median of 21.1%.
BTMD Competitors Peer median
Financing Cash Flow for BTMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$579.28M +999.4%+62.6%—
BTMDbiote Corp.LTM Mar 2026$62.84M -13.8%—33.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$52.98M -17.1%-13.5%—
LUCDLucid Diagnostics Inc.LTM Mar 2026$49.08M +8.7%+182.8%955.9%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$35.74M +16725.1%——
ACTUActuate Therapeutics IncLTM Mar 2026$24.02M +4.3%+7.2%—
ANIKAnika Therapeutics, Inc.LTM Mar 2026$15.46M -2.7%+29.6%13.3%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$13.15M +112.2%-52.5%1146.1%
JYNTThe Joint Corp.LTM Mar 2026$11.87M -1411.6%—20.9%
SCLXScilex Holding CompanyLTM Mar 2026$7.2M +171.8%—21.3%
SPROSpero Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding BTMD) $18.59M+8.7%+18.4%21.1%

Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income32.62M1.32M3.32M46K27.05M
Depreciation & Amortization1.4M2.2M2.99M3.57M3.67M
Deferred Income Tax0(743K)721K(2.9M)3.98M
Stock-Based Compensation082.18M9.06M8.74M8.92M
Change in Working Capital(1.46M)(35.81M)(8.93M)9.93M(8.25M)
Accounts Receivables(752K)(1.56M)(505K)(2.27M)(958K)
Inventory(5.76M)(1.71M)(6.1M)3.71M(6.24M)
Accounts Payables1.61M416K(165K)1.55M1.01M
Other Working Capital3.45M(32.96M)(2.16M)6.94M(2.06M)
Other Non-Cash Items1.16M(58.3M)19.72M25.85M(165K)
Operating Cash Flow33.72M(9.16M)26.88M45.24M35.19M
Capital Expenditures(3.81M)(1.84M)(2.71M)(6.43M)(5.02M)
Acquisitions (Net)000(11.84M)0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(2.36M)(1.51M)(2.35M)(526K)(1.85M)
Investing Cash Flow(3.81M)(1.84M)(2.71M)(18.8M)(6.86M)
Debt Repayment(5M)84.38M(6.25M)(6.25M)(1.25M)
Common Stock Issued0442K144K282K368K
Common Stock Repurchased0(424K)0(5.6M)(3.37M)
Dividends Paid(11.4M)(12.89M)(8.69M)(4.74M)(1.73M)
Other Financing Activities(3.94M)(8.05M)420K(59.77M)(37.58M)
Financing Cash Flow(20.34M)63.46M(14.38M)(76.08M)(43.56M)
Effect of Forex Changes(12K)0(19K)(22K)6K
Net Change in Cash9.56M52.47M9.77M(49.66M)(15.22M)
Free Cash Flow29.91M(11M)24.17M38.81M30.18M

biote Corp.

NASDAQ:BTMD

Intrinsic Alpha fair value

Locked

Current Price

$1.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.